Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.71 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.71 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4270033 | 1.00 | TRPV1 (0.71) | TRPV1TRPA1KCNH2TRPM8 | |
| SCHEMBL2724953 | 0.91 | TRPV1 (0.81) | TRPV1TRPA1KCNH2TRPM8 | |
| SCHEMBL4269875 | 0.91 | TRPV1 (0.81) | TRPV1TRPA1KCNH2TRPM8 | |
| SCHEMBL6705162 | 0.90 | TRPV1 (0.62) | TRPV1TRPA1KCNH2TRPM8 | |
| SCHEMBL4261287 | 0.90 | TRPV1 (0.69) | TRPV1TRPA1KCNH2TRPM8 | |
| SCHEMBL4271831 | 0.90 | TRPV1 (0.69) | TRPV1TRPA1KCNH2TRPM8 | |
| SCHEMBL4419550 | 0.89 | TRPV1 (0.70) | TRPV1TRPA1KCNH2TRPM8 | |
| SCHEMBL15779633 | 0.89 | TRPV1 (0.62) | TRPV1TRPA1KCNH2TRPM8 | |
| SCHEMBL15779648 | 0.89 | TRPV1 (0.62) | TRPV1TRPA1KCNH2TRPM8 | |
| SCHEMBL4266141 | 0.89 | TRPV1 (0.69) | TRPV1TRPA1KCNH2TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176443-A1 | Capsaicin receptor ligands | NEUROGEN CORPORATION | 2004-09-09 | — | — | US | claimed |
| US-6723730-B2 | DIARYL PIPERAZINES AND RELATED COMPOUNDS USEFUL IN THE TREATMENT OF A CHRONIC AND ACUTE PAIN CONDITIONS, ITCH AND URINARY INCONTINENCE. | NEUROGEN CORPORATION | 2004-04-20 | — | — | US | claimed |
| EP-1301484-A2 | CAPSAICIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2003-04-16 | — | — | EP | claimed |
| US-20020132853-A1 | Capsaicin receptor ligands | NEUROGEN CORPORATION | 2002-09-19 | — | — | US | claimed |
| WO-2002008221-A2 | CAPSAICIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2002-01-31 | — | — | WO | claimed |
| US-20090082362-A1 | Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure | BAKTHAVATCHALAM RAJAGOPAL | 2009-03-26 | — | — | US | disclosed |
| US-20090082362-A1 | Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure | BAKTHAVATCHALAM RAJAGOPAL | 2009-03-26 | — | — | US | disclosed |
| EP-2033951-A2 | 2-Piperazine-pyridines useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2009-03-11 | — | — | EP | disclosed |
| US-7256193-B2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2007-08-14 | — | — | US | disclosed |
| US-7256193-B2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2007-08-14 | — | — | US | disclosed |
| EP-1581225-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | NEUROGEN CORPORATION (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040142958-A1 | Combination therapy for the treatment of pain | NEUROGEN CORPORATION | 2004-07-22 | — | — | US | disclosed |
| WO-2004054582-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | NEUROGEN CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| US-6723730-B2 | DIARYL PIPERAZINES AND RELATED COMPOUNDS USEFUL IN THE TREATMENT OF A CHRONIC AND ACUTE PAIN CONDITIONS, ITCH AND URINARY INCONTINENCE. | NEUROGEN CORPORATION | 2004-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176443-A1 | Capsaicin receptor ligands | TRPV1, TRPV5, TRPV2 | TRPV1 1/4885TRPA1 4/4885KCNH2 403/4885 |
| US-20090082362-A1 | Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure | TRPV1, TRPA1, TRPV5 | TRPV1 1/4885TRPA1 2/4885KCNH2 641/4885 |
| US-20040142958-A1 | Combination therapy for the treatment of pain | OPRK1, OPRL1, OPRM1 | TRPV1 36/4885TRPA1 101/4885KCNH2 442/4885 |
| US-20020132853-A1 | Capsaicin receptor ligands | TRPV1, TRPV5, TRPV2 | TRPV1 1/4885TRPA1 4/4885KCNH2 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.